Effects of dopaminergic drugs on the mast cell degranulation and nitric oxide generation in RAW 264.7 cells

Arch Pharm Res. 2004 Jan;27(1):94-8. doi: 10.1007/BF02980053.

Abstract

Effects of dopaminergic drugs on the degranulation of mast cells (RBL-2H3 cells) and the nitric oxide production from macrophage cells (RAW 264.7) were studied. Among the dopaminergic agonists and antagonists tested, bromocriptine, 7-OH-DPAT, haloperidol, and clozapine showed potent inhibitions of mast cell degranualtion (IC50 value, 5 microM). However, these dopaminergic agents did not affect the tyrosine phosphorylations of the signaling components of the high affinity IgE receptor (FcepsilonRI), such as Syk, PLCgamma1, and PLCgamma2.; This suggested that these signaling components were not involved in the inhibition of the mast cell degranulation by these compounds. On the other hand, dopamine, bromocriptine, 7-OH-DAPT, and haloperidol markedly inhibited the nitric oxide production from RAW 264.7 cells (IC50 values, 10-20 microM). Bromocriptine, a dopamine agonist that is routinely used for the treatment of Parkinsons disease, inhibited the expression of the inducible nitric oxide synthase at an early stage of the LPS-induced protein expression in a dose-dependent manner. The results suggested that these dopaminergic agents, when used for the treatment of dopamine receptors-related diseases, such as Schizophrenia or Parkinsons disease, might have additional beneficial effects.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bromocriptine / pharmacology
  • Cell Degranulation / drug effects
  • Cell Degranulation / physiology
  • Cell Line, Tumor*
  • Clozapine / pharmacology
  • Dopamine / pharmacology
  • Dopamine Agents / pharmacology*
  • Dose-Response Relationship, Drug
  • Drug Evaluation, Preclinical / methods
  • Enzyme Precursors / metabolism
  • Enzyme Precursors / pharmacology
  • Haloperidol / pharmacology
  • Intracellular Signaling Peptides and Proteins
  • Lipopolysaccharides / pharmacology
  • Mast Cells / cytology*
  • Mast Cells / physiology
  • Mice
  • Nitric Oxide / antagonists & inhibitors
  • Nitric Oxide / biosynthesis*
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitric Oxide Synthase / biosynthesis
  • Nitric Oxide Synthase / genetics
  • Nitric Oxide Synthase Type II
  • Nitrites / metabolism
  • Phospholipase C gamma
  • Protein-Tyrosine Kinases / metabolism
  • Protein-Tyrosine Kinases / pharmacology
  • Quercetin / pharmacology
  • Receptors, IgE / drug effects
  • Signal Transduction / physiology
  • Syk Kinase
  • Tetrahydronaphthalenes / pharmacology
  • Type C Phospholipases / metabolism
  • Type C Phospholipases / pharmacology
  • beta-N-Acetylhexosaminidases / antagonists & inhibitors
  • beta-N-Acetylhexosaminidases / metabolism

Substances

  • Dopamine Agents
  • Enzyme Precursors
  • Intracellular Signaling Peptides and Proteins
  • Lipopolysaccharides
  • Nitrites
  • Receptors, IgE
  • Tetrahydronaphthalenes
  • Nitric Oxide
  • Bromocriptine
  • Quercetin
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Nos2 protein, mouse
  • Protein-Tyrosine Kinases
  • Syk Kinase
  • Syk protein, mouse
  • Type C Phospholipases
  • Phospholipase C gamma
  • beta-N-Acetylhexosaminidases
  • Clozapine
  • Haloperidol
  • 7-hydroxy-2-N,N-dipropylaminotetralin
  • Dopamine